Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | Outperform | William Blair | |
| 9/30/2024 | $20.00 | Sector Outperform | Scotiabank |
| 9/10/2024 | $15.00 | Mkt Outperform | JMP Securities |
| 7/9/2024 | $18.00 | Buy | Craig Hallum |
| 5/23/2024 | $21.00 | Overweight | Cantor Fitzgerald |
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced a formulation development collaboration with Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives. The partnership aims to develop a higher concentration formulation of Skye's CB1 inhibitor, nimacimab, using Arecor's proprietary formulation technology platform, Arestat™. Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase 2a CBeyond™ clinical
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on May 7, 2025, the Board of Directors granted a non-qualified stock option award to purchase 100,000 shares of its common stock to one new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the "2024 Inducement Plan"). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which both exhibited increasing dose-dependent brain penetration • This model predicts nimacimab's potentially superior therapeutic index, which is dependent on minimal brain exposure while maintaining sufficient peripheral inhibition SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic he
8-K - Skye Bioscience, Inc. (0001516551) (Filer)
10-Q - Skye Bioscience, Inc. (0001516551) (Filer)
DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)
SC 13G/A - Skye Bioscience, Inc. (0001516551) (Subject)
SC 13G/A - Skye Bioscience, Inc. (0001516551) (Subject)
SC 13G - Skye Bioscience, Inc. (0001516551) (Subject)
William Blair initiated coverage of Skye Bioscience with a rating of Outperform
Scotiabank initiated coverage of Skye Bioscience with a rating of Sector Outperform and set a new price target of $20.00
JMP Securities initiated coverage of Skye Bioscience with a rating of Mkt Outperform and set a new price target of $15.00
3 - Skye Bioscience, Inc. (0001516551) (Issuer)
4/A - Skye Bioscience, Inc. (0001516551) (Issuer)
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. "Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions," said Punit Dhillon, CEO of Skye. "In Q2, at our event, ‘Metabolic Rewiring wi
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company's operational and clinical expertise. Our strategic focus on the Nimacimab metabolic program will be supported by an evolving board as Keith Ward, PhD, and Praveen Tyle, PhD, resign from their roles as Boa
Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonistsExpanded preclinical study data to be presented at ADA in June 2025Top-line data readout from CBeyond™ Phase 2a study of nimacimab expected late Q3/early Q4 2025 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage b
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the c
Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removedPhase 2a dosing extended to 52 weeks to enhance long-term safety, tolerability, and efficacy dataCash runway projected through at least Q1 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial resu